Comment
doi: 10.1016/S0140-6736(21)01289-7.
Epub 2021 Jun 4.
CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
Affiliations
- PMID: 34097851
- DOI: 10.1016/S0140-6736(21)01289-7
Item in Clipboard
Comment
CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
Lancet.
.
No abstract available
Comment on
-
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097852 Free PMC article. Clinical Trial.
Similar articles
-
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z. J Hematol Oncol. 2016. PMID: 27887660 Free PMC article. Clinical Trial.
-
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4. Leuk Lymphoma. 2019. PMID: 30714847
-
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.Lancet Haematol. 2020 Nov;7(11):e816-e826. doi: 10.1016/S2352-3026(20)30277-5. Lancet Haematol. 2020. PMID: 33091355
-
Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.Ann Hematol. 2021 Feb;100(2):587-589. doi: 10.1007/s00277-020-04227-8. Epub 2020 Aug 22. Ann Hematol. 2021. PMID: 32829460 Free PMC article. No abstract available.
-
CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.Br J Haematol. 2020 Nov;191(4):617-626. doi: 10.1111/bjh.17153. Br J Haematol. 2020. PMID: 33190266 Review.
Cited by
-
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.Cancers (Basel). 2022 Dec 3;14(23):5983. doi: 10.3390/cancers14235983. Cancers (Basel). 2022. PMID: 36497465 Free PMC article. Review.
-
Management of neuropsychiatric adverse events in a prostate cancer patient undergoing chimeric antigen receptor T-cell immunotherapy (a phase I clinical trial): A case report.Asia Pac J Oncol Nurs. 2023 Mar 3;10(4):100211. doi: 10.1016/j.apjon.2023.100211. eCollection 2023 Apr. Asia Pac J Oncol Nurs. 2023. PMID: 37025985 Free PMC article.
-
CTLA-4 tail fusion enhances CAR-T antitumor immunity.Nat Immunol. 2023 Sep;24(9):1499-1510. doi: 10.1038/s41590-023-01571-5. Epub 2023 Jul 27. Nat Immunol. 2023. PMID: 37500885 Free PMC article.
-
Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs.Sci Signal. 2024 Jul 23;17(846):eadp8569. doi: 10.1126/scisignal.adp8569. Epub 2024 Jul 23. Sci Signal. 2024. PMID: 39042728 Free PMC article.
-
Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review.Front Oncol. 2024 Jan 23;14:1341682. doi: 10.3389/fonc.2024.1341682. eCollection 2024. Front Oncol. 2024. PMID: 38322417 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
